Oligonucleotide (siRNA) · developed by Arrowhead Pharmaceuticals
ARC-520 is an investigational small interfering RNA (siRNA) oligonucleotide studied in chronic hepatitis B.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02604199 | Phase 2 | Hepatitis B | Terminated | ARWR |
| NCT02065336 | Phase 2 | Hepatitis B, Chronic | Terminated | ARWR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatitis BHepatitis B, Chronic
See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARWR catalysts and pipeline →